SCHEMBL665932

SCHEMBL665932

CCn1cc(C)c2ccccc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.56
KMT2A Q03164 6/20 0.56
NR4A2 P43354 1/20 0.51
HDAC1 Q13547 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48
MAPT P10636 2/20 0.47
BRCA1 P38398 1/20 0.47
ALDH1A1 P00352 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
CYP19A1 P11511 1/20 0.46
TBXAS1 P24557 1/20 0.46
LMNA P02545 1/20 0.46
NPC1 O15118 1/20 0.45
USP2 O75604 1/20 0.45
RAB9A P51151 1/20 0.45
ATM Q13315 1/20 0.45
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15241823 0.86 MEN1 (0.54) MEN1KMT2ANR4A2HDAC1HDAC2
SCHEMBL10865240 0.85 ALDH1A1 (0.55) MEN1KMT2ANR4A2MAPTBRCA1
SCHEMBL8612793 0.84 CNR2 (0.56) MEN1KMT2AALDH1A1POLB
SCHEMBL4520729 0.82 MEN1 (0.54) MEN1KMT2AHDAC1HDAC2HDAC8
SCHEMBL8186052 0.82 MEN1 (0.58) MEN1KMT2ANR4A2HDAC1HDAC2
SCHEMBL12206640 0.81 CNR2 (0.54) MEN1KMT2AALDH1A1
SCHEMBL20221429 0.80 MEN1 (0.53) MEN1KMT2AHDAC1HDAC2HDAC8
SCHEMBL7712112 0.80 CNR2 (0.59)
SCHEMBL10396791 0.79 NR4A2 (0.51) MEN1KMT2ANR4A2MAPTBRCA1
SCHEMBL11622484 0.79 MEN1 (0.55) MEN1KMT2AHDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6391917-B1 ANALGESIC ZYMOGENETICS, INC. 2002-05-21 US claimed
US-6255351-B1 TREATMENT OF BONE DISORDERS ZYMOGENETICS, INC. 2001-07-03 US claimed
US-6221913-B1 Dialkyl ureas as calcitonin mimetics ZYMOGENETICS, INC. 2001-04-24 US claimed
US-6143932-A FOR EFFECTING ANALGESIA, A DECREASE IN THE POSTPRANDIAL RISE IN THE BLOOD GLUCOSE LEVELS OF A MAMMAL AFTER INGESTION OF A CARBOHYDRATE LOAD BY SAID MAMMAL, AND TREATING MICROBIAL INFECTIONS TREGA BIOSCIENCES, INC. (US) 2000-11-07 US claimed
EP-0975589-A2 DIALKYL UREAS AS CALCITONIN MIMETICS ZymoGenetics, Inc. (US) 2000-02-02 EP claimed
EP-0890101-A4 SELECTIVELY N-ALKYLATED PEPTIDOMIMETIC COMBINATORIAL LIBRARIES AND COMPOUNDS THEREIN TORREY PINES INST (US) 1999-12-08 EP claimed
WO-1999037604-A2 DIALKYL UREAS AS CALCITONIN MIMETICS ZYMOGENETICS, INC. (US) 1999-07-29 WO claimed
EP-0890101-A1 SELECTIVELY N-ALKYLATED PEPTIDOMIMETIC COMBINATORIAL LIBRARIES AND COMPOUNDS THEREIN TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) 1999-01-13 EP claimed
US-5859190-A SOLID PHASE SYNTHESIS TO FORM A PROTECTED DIPEPTIDE FOLLOWED BY REACTING WITH 1,1'-THIOCARBONYLDIIMIDAZOLE TO EFFECT RING FORMATION; EFFICIENCY; ANTICONVULSANT,-ARRHYTHMIC AND DIABETIC AGENTS; HERBICIDES AND FUNGICIDES TREGA BIOSCIENCES, INC. (US) 1999-01-12 US claimed
EP-0457195-B1 Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same FUJISAWA PHARMACEUTICAL CO (JP) 1998-04-15 EP claimed
WO-1997033174-A1 SELECTIVELY N-ALKYLATED PEPTIDOMIMETIC COMBINATORIAL LIBRARIES AND COMPOUNDS THEREIN TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) 1997-09-12 WO claimed
US-5656604-A HYPOTENSIVE AGENT; ENDOTHELIN ANTAGONIST FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-08-12 US claimed
US-5430022-A Endothelin antagonists; hypotensive agents; treatment for angina pectoris, brain disorders, asthma, renal failure FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-07-04 US claimed
US-5284828-A Hypotensive agents FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 1994-02-08 US claimed
CN-1057269-A Peptide compounds and preparation thereof FUJISAWA PHARMACEUTICAL CO (JP) 1991-12-25 CN claimed
EP-0457195-A2 Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-11-21 EP claimed
WO-2023109932-A1 DSRNA AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海拓界生物医药科技有限公司 2023-06-22 WO disclosed
US-20220306654-A1 MECHANOREDOX REACTION USING PIEZOELECTRIC MATERIAL, AND PRODUCTION METHOD USING SAID REACTION NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2022-09-29 US disclosed
US-4443615-A ANILINE, GLYCOL OR EPOXIDE, SILICA AND/OR ALUMINA CATALYST TANABE SEIYAKU CO., LTD. (JP) 1984-04-17 US disclosed
US-4072519-A Photoconductive composition, and element XEROX CORPORATION (US) 1978-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220306654-A1 MECHANOREDOX REACTION USING PIEZOELECTRIC MATERIAL, AND PRODUCTION METHOD USING SAID REACTION PIEZO1, PPOX, TAOK1 MEN1 269/4885KMT2A 3932/4885NR4A2 3344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.